PL2707017T3 - Liksisenatyd i metformina do leczenia cukrzycy typu 2 - Google Patents

Liksisenatyd i metformina do leczenia cukrzycy typu 2

Info

Publication number
PL2707017T3
PL2707017T3 PL12723132T PL12723132T PL2707017T3 PL 2707017 T3 PL2707017 T3 PL 2707017T3 PL 12723132 T PL12723132 T PL 12723132T PL 12723132 T PL12723132 T PL 12723132T PL 2707017 T3 PL2707017 T3 PL 2707017T3
Authority
PL
Poland
Prior art keywords
lixisenatide
metformin
treatment
diabetes type
diabetes
Prior art date
Application number
PL12723132T
Other languages
English (en)
Inventor
Peter Ruus
Louise Silvestre
Patrick Miossec
Jean-Louis Pinquier
Agnes Hincelin-Mery
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46148833&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2707017(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of PL2707017T3 publication Critical patent/PL2707017T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL12723132T 2011-05-13 2012-05-11 Liksisenatyd i metformina do leczenia cukrzycy typu 2 PL2707017T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP11166120 2011-05-13
EP12163637 2012-04-10
PCT/EP2012/058747 WO2012156298A1 (en) 2011-05-13 2012-05-11 Lixisenatide and metformin for treatment of diabetes type 2
EP12723132.2A EP2707017B1 (en) 2011-05-13 2012-05-11 Lixisenatide and metformin for treatment of diabetes type 2

Publications (1)

Publication Number Publication Date
PL2707017T3 true PL2707017T3 (pl) 2016-03-31

Family

ID=46148833

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12723132T PL2707017T3 (pl) 2011-05-13 2012-05-11 Liksisenatyd i metformina do leczenia cukrzycy typu 2

Country Status (20)

Country Link
US (1) US20130065828A1 (pl)
EP (1) EP2707017B1 (pl)
JP (2) JP6442284B2 (pl)
KR (1) KR20140043755A (pl)
CN (2) CN103841988A (pl)
AU (1) AU2012257849B2 (pl)
BR (1) BR112013029062A2 (pl)
CA (1) CA2835259C (pl)
CY (1) CY1117250T1 (pl)
DK (1) DK2707017T3 (pl)
ES (1) ES2556466T3 (pl)
HK (1) HK1194307A1 (pl)
HR (1) HRP20151369T1 (pl)
HU (1) HUE028459T2 (pl)
MX (1) MX362527B (pl)
PL (1) PL2707017T3 (pl)
PT (1) PT2707017E (pl)
RU (1) RU2623023C2 (pl)
SI (1) SI2707017T1 (pl)
WO (1) WO2012156298A1 (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX344293B (es) 2008-10-17 2016-12-13 Sanofi Aventis Deutschland Combinacion de una insulina y un agonista de glp-1.
PT2498802E (pt) 2009-11-13 2015-04-13 Sanofi Aventis Deutschland Composição farmacêutica que compreende um agonista de glp-1, uma insulina e metionina
BR112012011403B8 (pt) 2009-11-13 2021-05-25 Sanofi Aventis Deutschland composição farmacêutica líquida compreendendo um agonista glp-1 e metionina e uso da mesma
RU2546520C2 (ru) 2010-08-30 2015-04-10 Санофи-Авентис Дойчланд Гмбх Применение ave0010 для производства лекарственного средства для лечения сахарного диабета 2 типа
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
US9408893B2 (en) 2011-08-29 2016-08-09 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
TWI641381B (zh) 2013-02-04 2018-11-21 法商賽諾菲公司 胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物
WO2015104314A1 (en) 2014-01-09 2015-07-16 Sanofi Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
SG11201604708VA (en) 2014-01-09 2016-07-28 Sanofi Sa Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives
CN105899190B (zh) 2014-01-09 2022-06-14 赛诺菲 门冬胰岛素的稳定化药物制剂
LT3229828T (lt) 2014-12-12 2023-06-12 Sanofi-Aventis Deutschland Gmbh Insulino glargino/liksisenatido fiksuoto santykio kompozicija
TWI706779B (zh) * 2015-01-16 2020-10-11 德商賽諾菲阿凡提斯德意志有限公司 小兒第２型糖尿病病患之治療
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
CN101014360A (zh) * 2004-08-03 2007-08-08 埃米斯菲尔技术公司 抗糖尿病口服胰岛素－双胍组合物
CN101291685A (zh) * 2005-08-19 2008-10-22 安米林药品公司 治疗糖尿病和降低体重的毒蜥外泌肽
EP2057188B1 (en) * 2006-08-17 2013-07-31 Amylin Pharmaceuticals, LLC Dpp-iv resistant gip hybrid polypeptides with selectable properties
CN117547538A (zh) * 2009-02-13 2024-02-13 勃林格殷格翰国际有限公司 包含dpp-4抑制剂(利格列汀)任选地组合其它抗糖尿病药的抗糖尿病药物
US20110118178A1 (en) * 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metformin
US20110118180A1 (en) * 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Method of treatment of diabetes type 2 comprising add-on therapy to metformin
HUE026489T2 (en) 2009-11-13 2016-06-28 Sanofi Aventis Deutschland Combination of lixisenatide and metformin to treat type 2 diabetes

Also Published As

Publication number Publication date
WO2012156298A1 (en) 2012-11-22
JP6442284B2 (ja) 2018-12-19
KR20140043755A (ko) 2014-04-10
RU2013155474A (ru) 2015-06-20
JP2018184441A (ja) 2018-11-22
CN107693782A (zh) 2018-02-16
EP2707017B1 (en) 2015-09-16
CA2835259C (en) 2020-01-07
CN103841988A (zh) 2014-06-04
PT2707017E (pt) 2016-01-12
ES2556466T3 (es) 2016-01-18
MX2013013307A (es) 2014-03-12
JP6676108B2 (ja) 2020-04-08
CY1117250T1 (el) 2017-04-05
JP2014514356A (ja) 2014-06-19
DK2707017T3 (en) 2016-01-04
HK1194307A1 (en) 2014-10-17
US20130065828A1 (en) 2013-03-14
CA2835259A1 (en) 2012-11-22
BR112013029062A2 (pt) 2016-11-29
AU2012257849B2 (en) 2017-03-30
SI2707017T1 (sl) 2016-01-29
EP2707017A1 (en) 2014-03-19
MX362527B (es) 2019-01-23
RU2623023C2 (ru) 2017-06-21
HRP20151369T1 (hr) 2016-01-15
HUE028459T2 (en) 2016-12-28

Similar Documents

Publication Publication Date Title
PT2707017E (pt) Lixisenatida e metformina para tratamento da diabetes tipo 2
IL252699A0 (en) Use of lequinimod to treat multiple sclerosis
HK1198577A1 (en) Treatment protocol of diabetes type 2
ZA201403795B (en) Formulations for the treatment of diabetes
RS63305B1 (sr) Ko-agonisti glukagona i glp-1 za lečenje gojaznosti
PL2683395T3 (pl) Zastosowanie małych dawek il-2 do leczenia cukrzycy typu 1
EP2675459A4 (en) COMPOUNDS AND METHODS FOR TREATING DIABETES
EP2670434A4 (en) TREATMENT OF TAUOPATHIA
IL223289A0 (en) Treatment of type 2 diabetes
IL228771A0 (en) Glycoside history and their use in the treatment of diabetes
EP2867239A4 (en) OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF DIABETES
HUE038787T2 (hu) Tripeptid készítmények és alkalmazásuk diabétesz kezelésére
SG11201408717XA (en) Stem cells and pancreatic cells useful for the treatment of insulin-dependent diabetes mellitus
EP2774917A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DIABETES
HK1257401A1 (zh) 用於治療糖尿病和相關病症的方法和組合物
ZA201408065B (en) Compositions and methods for the treatment of diabetes
HK1202819A1 (en) Treatment of type i and type ii diabetes i ii
EP2402342A4 (en) PHARMACEUTICAL COMPOSITION FOR TREATING TYPE 2 DIABETES
EP2680846A4 (en) USE OF N- (4-METHOXYPHENYL) -1-PHENYL-1H-PYRAZOL-3-AMINE AND COMPOUNDS ASSOCIATED THEREWITH
GB0919603D0 (en) Use of thymosin beta-4 for treatment of type II diabetes
HK1198467A1 (en) Treatment of type 2 diabetes with fty720 fty720 2
EG27140A (en) Preparation and characterization of metformin as insulin resistant reducing agents for type ii diabetes
HK1196953A1 (zh) 用於治療糖尿病的製劑
PT2717872T (pt) Combinação sinérgica para o tratamento da diabetes mellitus tipo 2